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Abbreviations 
AAD  Anti-arrhythmia drug 
AF  Atrial fibrillation 
CVA  Cerebrovascular accident 
DCCV  Direct current cardioversion 
ECG  Electrocardiogram 
EDV  End-diastolic volume 
EF  Ejection fraction 
ELISA  Enzyme-linked immunosorbent assay 
EP  Electrophysiology 
FGF-23  Fibroblast growth factor 23 
Gal-3  Galectin-3 
ICTP  Type I collagen carboxyl telopeptide 
LA  Left atrium 
LV  Left ventricle 
MRI  Magnetic resonance imaging 
NT pro-BNP N-terminal pro-brain natriuretic peptide 
PIIINP   Procollagen type III N terminal peptide 
TIA  Transient ischaemic attack 
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Abstract 
Introduction. External direct current cardioversion (DCCV) is an established treatment for AF 
but is associated with procedural risk and high AF recurrence rates. Cardiac fibrosis has been 
associated with AF, and circulating biomarkers have been suggested as a method of its 
assessment, but which biomarkers are suitable is yet to be determined. This study examines 
the differences between levels of procollagen type III N terminal peptide (PIIINP), type I 
collagen carboxyl telopeptide (ICTP), galectin-3 (gal-3) and fibroblast growth factor 23 (FGF-
23) in DCCV patients, and disease-and-age-matched controls. Their predictive value for AF 
recurrence was analysed. 
Methods. 79 patients undergoing DCCV and 40 age-and-disease-matched controls were 
included. Biomarkers were analysed using ELISA. Linear regression was used to examine 
relationships between biomarker levels and baseline characteristics, including 
echocardiographic measurements. Cox regression was used to assess relationships between 
baseline characteristics, including biomarker levels, and AF recurrence. 
Results. There was no statistically significant difference between biomarker levels in the 
DCCV and control groups. Diabetes mellitus was related to higher FGF-23 (p=0.007) and 
PIIINP (p=0.027). Female sex (p=0.014), hypertension (p=0.001), and higher body mass index 
(p=<0.001) were related to higher gal-3 levels. FGF-23 was weakly predictive of AF 
recurrence (HR 1.003 p=0.012). 
Conclusion. PIIINP, ICTP, and Gal-3 are not predictive of AF recurrence after DCCV. FGF-23 
may be associated with arrhythmia recurrence, but further work is required to clarify this. 
The presence of AF has no effect on levels of these biomarkers when compared to age and 
disease-matched controls. 
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Highlights 
 Cardiac fibrosis is associated with AF, and biomarkers may detect this 
 Improvement in patient selection for cardioversion is desirable 
 Four biomarkers were studied (ICTP, galectin-3, PIIINP, and FGF-23) 
 A weak association between FGF-23 and AF recurrence was found 
 There were no biomarker differences between AF patients and controls 
Introduction 
Elective direct current cardioversion (DCCV) remains an established treatment for 
symptomatic persistent atrial fibrillation (AF).(1) It is immediately successful in up to 90% of 
cases, however more than half of patients will have experienced recurrence of AF after one 
year.(2,3) Even in anticoagulated patients, DCCV carries a small risk (approximately 1%) of 
arterial thromboembolism and stroke.(4) Improved assessment of the likelihood of 
recurrence may aid better patient selection for rhythm control with DCCV, reducing the 
number of patients unnecessarily exposed to this risk. 
 
Left atrial (LA) fibrosis has been associated with AF,(5) and recurrence of AF after rhythm 
control intervention. Clinical methods of assessment of this fibrosis include late gadolinium 
enhancement MRI, and invasive electrophysiological mapping. Both of these methods have 
been shown to have predictive value for arrhythmia recurrence after percutaneous 
ablation.(6,7) However, there is limited access to MRI, and EP mapping is an invasive test 
requiring direct access to the left atrium. Neither is therefore suitable for assessing the risk 
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of AF recurrence after cardioversion in usual clinical practice, and more practical methods 
are desirable. Such a method of assessment for DCCV patients may include the use of 
circulating biomarkers. Studies have assessed markers of inflammation, myocardial injury, 
and atrial stretch with varying levels of success.(8-13) A number of substances involved in 
fibrosis can be measured in peripheral blood and therefore have the potential to act as 
biomarkers. Evidence is conflicting regarding their use in rhythm control in general, and is 
sparse in the context of DCCV.(14-19) In this study, we examined type III procollagen N 
terminal peptide (PIIINP) and type I collagen carboxyl telopeptide (ICTP) - two direct 
markers of collagen turnover. We also included galectin-3 (gal-3), a more recently identified 
biomarker of fibrosis that is involved with a number of steps in the inflammatory-fibrotic 
process, and finally fibroblast growth factor 23 (FGF-23), a hormone principally studied in 
the context of phosphate homeostasis, but with recent evidence suggestive of a role in AF 
and possibly AF-related fibrosis.   
 
We designed a study to test the hypothesis that these four fibrosis biomarkers would 
predict AF recurrence after DCCV. We also hypothesised that these markers would be 
related to parameters of left atrial remodeling assessed by standard echocardiographic 
measurements, and would be higher in AF patients when compared to disease and age-
matched controls. 
 
Keywords 
Fibrosis; atrial fibrillation; cardioversion; biomarkers 
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Methods 
The study was approved by the National Research Ethics Service Committee – Leeds West 
(ref. 13/YH/0349). All patients recruited gave written informed consent. At a single 
institution, patients due for DCCV for atrial fibrillation were screened between October 
2014 and August 2015. Main inclusion criteria were the presence of persistent symptomatic 
AF requiring cardioversion and the ability to give informed consent. Main exclusion criteria 
were designed to avoid confounding by non-cardiac fibrotic pathology and included the 
presence of chronic kidney disease, malignancy, connective tissue disease or systemic 
inflammatory disease (e.g. interstitial lung disease or inflammatory bowel disease). Patients 
with a history of AF ablation were also excluded. 
 
Participants in the control group were selected from patients attending general cardiology 
clinic for non-arrhythmia related conditions or symptoms. Participants were selectively 
recruited to create a control cohort matched for age, gender and comorbidity with the 
DCCV cohort. Similar exclusion criteria were applied, with the presence of any history of AF, 
other sustained atrial arrhythmia, or undiagnosed palpitations additionally. 
 
External electrical cardioversions were carried out under general anaesthetic according to 
standard local clinical protocol. Patients were fasted for a minimum of six hours prior to 
induction of anaesthesia. Biphasic discharges, synchronized to the ECG R wave, were 
delivered up to a maximum of three times, using an escalating energy protocol of 100J, 
150J, 200J. Defibrillator patches were applied to the chest wall in antero-posterior 
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orientation. If sinus rhythm was not restored after three discharges, no further attempts at 
sinus rhythm restoration were made. 
 
Blood was taken from a peripheral vein prior to cardioversion and transferred to serum 
separator tubes for a minimum of 30 minutes. After coagulation, the tubes were centrifuged 
for 15 mins at 1600g. The separated serum was then aliquoted into sterile non-pyrogenic 
Eppendorf tubes and frozen at -70oC. Serum was thawed once, just prior to ELISA analysis. 
Samples were analysed using commercially available enzyme-linked immunosorbent assay 
(ELISA) kits. Pro-collagen type III N-terminal peptide (PIIINP) and galectin-3 (Gal-3) were 
analysed using kits produced by Elabscience (Beijing, China). Type I collagen C-terminal 
telopeptide (ICTP) was analysed using kits produced by Cusabio Life Science (Wuhan, China). 
Kits were processed according to the manufacturer’s instructions, and serial dilutions of 
serum were used to determine the appropriate dilution factor for each biomarker. 
Standards of known concentration and serum samples were tested in duplicate. Serum 
concentrations were extrapolated from optical density readings using a 4-parameter logistic 
curve derived from the standards, with background correction using blank wells. Inter- and 
intra-assay coefficients of variation were <15%. Minimum limits of detection were; ICTP = 25 
ng/mL, Gal-3 = 0.156 ng/mL, FGF-23 = 15.625 pg/mL, PIIINP = 23.438 pg/mL. 
 
All participants underwent trans-thoracic echocardiography prior to ablation, performed by 
a single operator with over 5 years’ experience. Images were obtained according to British 
Society of Echocardiography guidelines.(20) 
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Normally distributed data are expressed as ‘mean ± standard deviation’. Non-parametric 
data are expressed as ‘median (interquartile range)’. Categorical data are expressed as 
‘frequency (percentage)’. Normality of data was assessed using the Shapiro-Wilks test. 
Comparison between two groups was carried out using Student’s t test, for normal data. 
Where non-parametric data could not be transformed successfully, Mann-Whitney U test 
was used. Univariate linear regression was used to assess the effect of baseline 
characteristics on biomarker levels. Variables with significant effects in univariate analysis 
were then examined in multivariate linear regression analysis. Univariate Cox regression 
analysis was used to assess predictors of arrhythmia recurrence. A two-sided p value of 0.05 
was used to determine statistical significance. 
To calculate power, we hypothesized that there would be an increase of 0.5 standard 
deviations in the levels of biomarkers in AF patients compared to controls. In order to 
achieve this variance using criteria of 1-β = 0.8 and p<0.05, 35 patients per group would be 
required for the comparison part of the study. In order to achieve 80% statistical power to 
detect the difference in outcome based on biomarker levels, using p=0.05 to indicate 
significance, at least 20 AF recurrence events would be required. Therefore, target 
recruitment was set at 80 for the DCCV group and 40 for the control group. 
Results 
80 DCCV patients and 40 control patients were recruited. One patient was diagnosed with 
multiple myeloma after DCCV and died before follow up was complete. This patient’s data 
was excluded from analysis. Two further patients were lost to follow up. These patients 
were excluded from outcome analysis, but were included in baseline analysis.  
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DCCV patients vs. controls  
Valid biomarker results were obtained as follows: for the AF group, ICTP n= 76, Gal-3 n=74, 
PIIINP n=38, FGF-23 n= 27. For the control group, ICTP n = 35, Gal-3 = 36, PIIINP n = 31, FGF-
23 n = 12. The patient characteristics are summarised in table 1. LA volume and diameter 
were significantly higher in the DCCV group, but there were no other differences. Biomarker 
levels were not significantly different between the groups, although PIIINP levels were 
approaching significance for being higher in AF patients (p = 0.068). 
 
Table 1. Baseline characteristics and comparison between DCCV and control groups 
Characteristic DCCV Group n=80 Control Group n=40 P Value 
Age (years) 63.1 ± 9.9 62.2 ± 10.3 0.627 
BMI (kg/m2) 30.7 ± 7.2 29.0 ± 5.2 0.172 
Female sex 24 (30.0) 13 (32.5) 0.780 
Hypertension 42 (52.5) 21 (52.5) 1.000 
Diabetes Mellitus 9 (11.3) 6 (15) 0.558 
Ischaemic heart 
disease 
14 (17.5) 6 (15) 0.729 
Stroke or TIA 6 (7.5) 5 (12.5) 0.282 
Time since 1st AF 
diagnosis (months) 
6.6 (15.1) - - 
CHA2DS2VASc 
0 
1 
2 
3 
4 
5 
6 
 
14 (17.5) 
25 (31.3) 
17 (21.3) 
13 (16.3) 
7 (8.8) 
3 (3.8) 
1 (1.3) 
- - 
AAD 10 (12.5) - - 
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Rate – limiting drugs 
0 
1 
2 
3 
 
8 (10.0) 
58 (72.5) 
12 (15.0) 
2 (2.5) 
 
- 
 
- 
LA Volume (mL) 85.3 ± 25.8 56.4 ± 19.3 <0.001 
LA Diameter (mm) 44.4 ± 5.6 39.7 ± 5.9 <0.001 
LV EDV (mL) 105.3 ± 35.6 104.7 ± 32.5 0.941 
LV EF (%) 54.1 ± 11.9 59.0 ± 12.8 0.731 
Gal-3 (ng/mL) 25.2 (28.8) 25.9 (23.7) 0.194 
PIIINP (pg/mL) 53.5 (108.5) 42.7 (19.2) 0.068 
ICTP (ng/mL) 252.3 (190.4) 195.9 (315.2) 0.369 
FGF-23 (pg/mL) 31.5 (102.3) 91.8 (90.3) 0.916 
 
 
Baseline characteristics and relationship to biomarkers  
For each of the four biomarkers, regression analysis was carried out to show relationships 
with patient characteristics across the DCCV cohort. Full results of this analysis are shown in 
table 2. In summary, statistically significant results after multivariate analysis were: Diabetes 
was related to higher PIIINP and FGF-23 levels; higher BMI, female sex, and hypertension 
were related to higher gal-3 levels. 
 
Table 2. Regression analysis of biomarkers in relation to baseline characteristics, DCCV 
cohort. 
 
Characteristic PIIINP Gal-3 ICTP FGF-23 
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Beta P Value Beta P Value Beta P Value Beta P Value 
Age 0.306 
0.444 
0.061 
0.088 
-0.025 0.832 -0.063 0.588 -0.050 0.806 
BMI -0.079 0.639 0.538 
0.424 
<0.001 
<0.001 
0.073 0.528 -0.114 0.572 
Female sex 1.396 0.171 0.312 
0.273 
0.007 
0.014 
-0.260 
-0.194 
0.023 
0.116 
-0.178 0.374 
Time since AF 
diagnosis 
0.351 
0.173 
0.033 
0.296 
-0.112 0.353 -0.081 0.494 -0.082 0.689 
Hypertension 0.117 0.483 0.387 
0.398 
0.001 
0.001 
-0.132 0.254 -0.479 
-0.355 
0.012 
0.055 
DM 0.273 
0.411 
0.098 
0.027 
0.174 0.139 -0.120 0.303 0.463 
0.455 
0.015 
0.007 
IHD 0.323 
0.058 
0.048 
0.770 
-0.010 0.932 -0.052 0.654 -0.148 0.461 
CVA or TIA -0.031 0.855 0.022 0.852 -0.186 0.107 -0.156 0.437 
CHA2DS2VASc 0.365 
-0.279 
0.024 
0.365 
0.263 
-0.410 
0.024 
0.736 
-0.244 
-0.166 
0.034 
0.176 
-0.388 
-0.219 
0.046 
0.226 
LA volume -0.244 0.146 -0.008 0.945 0.136 0.892 -0.044 0.837 
LA diameter -0.331 
-0.205 
0.042 
0.245 
0.013 0.915 0.127 
0.144 
0.283 0.053 0.801 
LV EDV -0.299 
-0.106 
0.097 
0.556 
-0.033 0.796 -0.002 0.985 -0.002 0.993 
LV EF -0.044 0.800 0.227 
0.138 
0.066 
0.169 
-0.006 0.961 -0.077 0.735 
Values in italics = multivariate analysis. Bold = statisitically significant after multivariate 
analysis. 
 
 
Recurrence of AF after DCCV 
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Duration of follow up was 383 ± 54 days. 49 patients (61.3%) experienced AF recurrence 
within the duration of follow up. Median AF-free survival was 170 days. 
There were no significant differences between distribution of biomarker levels in patients 
with AF recurrence and those without. 
In univariate Cox regression analysis of all baseline characteristics (table 3), only FGF-23 was 
found to be weakly associated with arrhythmia recurrence (HR 1.003, p=0.012). 
 
Table 3. Univariate Cox regression analysis, AF recurrence 
Characteristic Hazard ratio P value 
Age 1.004 0.802 
BMI 1.013 0.506 
Female sex 0.624 0.124 
Time since first AF diagnosis 0.999 0.657 
Hypertension 0.831 0.519 
Diabetes mellitus 0.876 0.799 
IHD 0.681 0.351 
CVA or TIA 2.384 0.101 
CHA2DS2VASc 1.087 0.431 
LA volume 1.000 0.992 
LA diameter 1.000 0.994 
LV EDV 0.991 0.074 
LV EF 1.015 0.297 
PIIINP 1.002 0.292 
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Gal-3 1.002 0.778 
ICTP 1.001 0.382 
FGF-23 1.003 0.012 
ICTP / PIIINP ratio 1.022 0.607 
 
Discussion 
Selection of biomarkers 
The hallmark of fibrosis is an increase in volume and turnover of extracellular matrix (ECM). 
In the heart, ECM is comprised predominantly of type I, and to a lesser extent type III, 
collagen. PIIINP is cleaved from the pro-peptide of type III collagen in the extracellular space 
and thereby enters the bloodstream, so serves as a marker of the synthesis of type III 
collagen. It has been shown to be present in higher concentrations in LA tissue of AF 
patients.(21) ICTP is a product of the breakdown of type I collagen by matrix 
metalloproteinase 1.(22) By including both of these substances in the study, the aim was to 
assess turnover of ECM, so the ratio of type I collagen catabolism to type III collagen 
synthesis was examined by ICTP:PIIINP ratio, however this value was not related to baseline 
characteristics or outcome. 
 
Gal-3, a member of the lectin family, has been found to have diverse direct and indirect 
actions associated with fibrosis in multiple tissues. It is associated with the presence of 
myofibroblasts and macrophages, which have been shown to proliferate in cardiac fibrosis. 
It appears to have activity related to cell adhesion, growth and differentiation, apoptosis 
and chemo-attraction, and has been associated with fibrogenesis, inflammation and 
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ventricular remodeling.(23-25) It has been associated with risk of developing AF, both in the 
general population, and after myocardial infarction.(26,27) Studies assessing its association 
with arrhythmia recurrence after ablation have shown mixed results. (28,29) It has not been 
studied in the context of cardioversion previously. Higher levels have been associated with 
hypertension, female gender and higher BMI, and our findings agree.(30-32)  
 
FGF-23 has come to light in recent years in the context of its endocrine role in phosphate 
homeostasis. It has been studied principally in heart failure and kidney disease, and does 
appear to be related to cardiac outcomes in the latter, as well as independently of renal 
function.(33,34) In the fibrotic atrial myocardium found in AF, cardiomyocytes have been 
found to de-differentiate into a more primitive cell type.(35) FGF-23 has been shown in vitro 
to be required for cardiomyocyte proliferation and differentiation in early embryonic stages, 
and, speculatively, may have a role in the cardiomyocyte changes found in the fibrotic atria 
of AF patients, including calcium handling.(36) It has been associated with increased atrial 
wall tension manifest by NT-proBNP, but results of studies assessing its association with 
incident AF are mixed.(37,38) It has not been assessed in the context cardioversion 
previously. 
 
DCCV patients vs controls 
This study is, to our knowledge, unique in comparing AF patients selected for DCCV to age 
and disease-matched controls when assessing biomarkers of fibrosis. In this study, there 
was no difference between levels of the four biomarkers between the DCCV patients and 
controls, which were well-matched for age and comorbidities. PIIINP levels approached 
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significance for being higher in AF patients, suggesting that either there is no true 
difference, or perhaps that any true difference is so slight as to be undetectable in a study of 
this size. Overall these findings are suggestive that either the DCCV patients had similar 
levels of fibrosis to the controls, or any differences in fibrosis were not detectable using 
these biomarkers peripherally. This may be accounted for by the fact that the controls were 
not disease-free, and comorbidity in the control group may have accounted for a rise in 
biomarker levels, therefore masking any specific contribution of AF to biomarker levels in 
the DCCV cohort. It may be the comorbidities present in AF patients that cause the increase 
in fibrosis biomarkers noted in other studies. It should be noted that one of the limitations 
of this study is the impossibility of excluding non-symptomatic paroxysmal AF in the control 
group, however it is unlikely that this would have been a significant problem. 
Previously, Sonmez et al. showed higher levels of gal-3  and PIIINP in AF patients compared 
to sinus rhythm age-matched controls, in a slightly smaller study.(39) While controls in that 
study were matched for most baseline characteristics, there was significantly higher heart 
failure in the AF group. This may have had an important confounding influence on their 
results, as both PIIINP and, more convincingly, gal-3 have been associated with reduced LV 
systolic function.(28) Gurses et. al. did find significantly higher levels of gal-3 in AF patients, 
although in their study they excluded patients with reduced ejection fraction, which again 
makes comparison difficult.(40) Zakeri et al. found no gal-3 or PIIINP differences, and lower 
ICTP levels in controls.(41) However 23% of their sinus rhythm patients had a previous 
history of AF. They were also younger, with better LV function. In an AF ablation cohort, 
Kornej et al. also showed no difference between gal-3 in AF patients and controls after 
multivariate analysis.(28) If nothing else, these studies highlight that work in this field 
involves heterogenous patient groups between studies and it can therefore be difficult to 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
draw firm conclusions regarding the overall AF patient population. In our study, only left 
atrial dimensions were different between the groups. As left atrial remodeling is a known 
effect of AF, this is to be expected. As the controls appear to be more well-matched than in 
other studies, the results are more robust.  
 
Predictive value of the biomarkers  
PIIINP, ICTP and Gal-3 had no predictive value for recurrence of AF. FGF-23, however, was 
found to be significantly, but weakly associated with recurrence, with a hazard ratio of 1.003 
per 1 pg/mL increase in FGF-23 level. This result has not previously been reported, but must 
be interpreted with caution due to the low number of valid results for this biomarker 
compared to the overall number of patients, due to the limitations of the ELISA assay. It is 
possible that a more sensitive test may be able to explore this finding further. 
Gal-3 has not been studied in the context of DCCV, however in ablation results have been 
mixed. Kornej et. al. found no association between AF recurrence and gal-3 levels in their 
ablation cohort.(28) Conversely Wu et. al. did show that gal-3 was associated with AF 
recurrence after ablation, however this finding is in the context of a younger cohort with 
lone AF so, again, is not comparable with this study.(42) 
PIIINP was found to be independently associated with outcome by Kawamura et al. in their 
study of 142 patients undergoing pharmacological cardioversion, with DCCV if this 
failed.(17) Patients were followed up for 24 months. The baseline characteristics of patients 
in their study were similar to ours, with the notable exceptions of LV ejection fraction, which 
was lower in our cohort, and duration of AF which was much higher in our cohort. This may 
explain why this study did not reproduce their results, and we feel that our cohort more 
closely resembles ‘typical’ patients selected for DCCV, at least in our experience. 
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Finally Kallergis et. al. showed an association between recurrence and ICTP in their study of 
164 DCCV patients. Notably however, they excluded patients with a significant number of 
comorbidities which may make their findings difficult to generalize to the AF population. 
Conclusion 
PIIINP, ICTP, and Gal-3 are not predictive of AF recurrence after DCCV. FGF-23 may be 
associated with arrhythmia recurrence, but further work is required to clarify this. The 
presence of AF has no effect on levels of these biomarkers when compared to age and 
disease-matched controls. 
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